ERBB2 and metastatic colorectal cancer: Besides showing that the combination of pertuzumab and trastuzumab is an effective and well-tolerated treatment in patients with heavily pretreated HER2-amplified mCRC, it pointed to the importance of molecular profiling in identifying potential therapeutic targets such as HER2 amplification in metastatic colorectal cancer [52].